In a report released today, Dane Leone from BTIG maintained a Buy rating on Voyager Therapeutics Inc (NASDAQ: VYGR), with a price target of $32. The company’s shares closed on Friday at $19.31.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 19.9% and a 66.0% success rate. Leone covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, G1 Therapeutics Inc, and Bluebird Bio.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Voyager Therapeutics Inc with a $30.33 average price target.
See today’s analyst top recommended stocks >>
Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $25.54 million. In comparison, last year the company had a GAAP net loss of $18.88 million.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VYGR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
